BOSTON, MA, November 11, 2025 – Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics’ DNBSEQ-T1+ sequencing platform.  The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumor applications to customers globally. The announcement was made from the Association for Molecular Pathology (AMP) Annual Meeting in Boston.

The collaboration integrates SOPHiA GENETICS’ advanced, AI-powered applications MSK-IMPACT® and MSK-ACCESS® powered by SOPHiA DDM™, developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), with Complete Genomics’ newly launched DNBSEQ-T1+ sequencing platform. Together, Complete Genomics and SOPHiA GENETICS will provide an integrated, sample-to-report workflow for laboratories, marking a significant expansion of their partnership into the precision oncology research market.

“Pairing MSK-IMPACT® and MSK-ACCESS® powered with SOPHiA DDM™ with our DNBSEQ-T1+ platform creates a powerful and accessible solution for laboratories looking to scale high-quality cancer genomic profiling,” said Rob Tarbox, vice president of product and marketing at Complete Genomics. “By combining MSK’s rigorously validated assays, SOPHiA GENETICS’ robust analytics, and our sequencing technology, we are enabling decentralized labs to deliver faster, more accurate, and more affordable insights to clinicians and researchers.”

“This collaboration underscores SOPHiA GENETICS’ commitment to broadening access to data-driven medicine,” said Ross Muken, President,SOPHiA GENETICS. “Partnering with Complete Genomics to streamline use of MSK-IMPACT® and MSK-ACCESS® powered with SOPHiA DDM™ on the DNBSEQ-T1+ platform enables more laboratories around the world to adopt precision oncology through scalable, end-to-end genomic solutions.”

The DNBSEQ-T1+, powered by proprietary DNBSEQ technology, delivers Q40-level accuracy, optimized throughput from 500 million to 2 billion reads per flow cell. Each flow cell is able to be run independently, with a 24-hour paired-end 150bp run time, offering laboratories a cost-effective and highly flexible sequencing solution. At maximum throughput, each T1+ flow cell can run up to  60 tumor-normal sample pairs for tissue, up to 16 tumor-normal sample pairs for liquid biopsy.

SOPHiA DDM™ is a technology-agnostic analytics platform that leverages AI to compute, standardize, and analyze healthcare data. Joint evaluation of MSK-IMPACT® and MSK-ACCESS® on the DNBSEQ-T1+ platform demonstrated highly concordant variant calls and allele frequencies compared with equivalent sequencing systems, while achieving lower background noise, reduced turnaround time, and seamless compatibility with existing SOPHiA DDM™ workflows.

This new offering provides clinical laboratories, cancer centers, and drug developers with a high-performance, cost-efficient path to implementing comprehensive genomic profiling for precision oncology research.

To learn more, visit the Complete Genomics Booth 1210 or SOPHiA GENETICS Booth 921 at AMP from November 11–15, 2025 or visit www.CompleteGenomics.com and  www.SOPHiAGENETICS.com.

About Complete Genomics

Complete Genomics is a pioneering life sciences company that provides novel, complete sequencing solutions including sample/library preparation, lab automation, sequencing, and data analysis. The sequencing portfolio offers a full lineup of sequencers ranging from low, medium, and high throughput capacities, all powered by its proprietary DNBSEQ technology. More than 10,900 publications are based on DNBSEQ technology across a wide array of applications. To learn more, visit www.completegenomics.com.

* For Research Use Only. Not for use in diagnostic procedures.